| 000 | 01562 a2200397 4500 | ||
|---|---|---|---|
| 005 | 20250513183950.0 | ||
| 264 | 0 | _c19990720 | |
| 008 | 199907s 0 0 eng d | ||
| 022 | _a1387-2273 | ||
| 024 | 7 |
_a10.1016/s0378-4347(99)00098-5 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHartleb, J | |
| 245 | 0 | 0 |
_aDetermination of 5-S-cysteinyldopa in plasma and urine using a fully automated solid-phase extraction--high-performance liquid chromatographic method for an improvement of specificity and sensitivity of this prognostic marker of malignant melanoma. _h[electronic resource] |
| 260 |
_bJournal of chromatography. B, Biomedical sciences and applications _cApr 1999 |
||
| 300 |
_a31-42 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAutomation |
| 650 | 0 | 4 |
_aBiomarkers, Tumor _xblood |
| 650 | 0 | 4 | _aCalibration |
| 650 | 0 | 4 | _aCase-Control Studies |
| 650 | 0 | 4 |
_aChromatography, High Pressure Liquid _xmethods |
| 650 | 0 | 4 |
_aCysteinyldopa _xblood |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMelanoma _xblood |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aReference Standards |
| 650 | 0 | 4 | _aReproducibility of Results |
| 650 | 0 | 4 | _aSensitivity and Specificity |
| 650 | 0 | 4 |
_aSkin Neoplasms _xblood |
| 700 | 1 | _aDamm, Y | |
| 700 | 1 | _aArndt, R | |
| 700 | 1 | _aChristophers, E | |
| 700 | 1 | _aStockfleth, E | |
| 773 | 0 |
_tJournal of chromatography. B, Biomedical sciences and applications _gvol. 727 _gno. 1-2 _gp. 31-42 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0378-4347(99)00098-5 _zAvailable from publisher's website |
| 999 |
_c10318999 _d10318999 |
||